| 000 | 01813 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250512113325.0 | ||
| 264 | 0 | _c19720627 | |
| 008 | 197206s 0 0 eng d | ||
| 022 | _a0021-9754 | ||
| 024 | 7 |
_a10.1002/j.1552-4604.1972.tb00043.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSimpson, G M | |
| 245 | 0 | 0 |
_aSome methodological considerations in the evaluation of drug-induced extrapyramidal disorders: a study of Ex10-029, a new morphanthridine derivative. _h[electronic resource] |
| 260 |
_bThe Journal of clinical pharmacology and new drugs _cApr 1972 |
||
| 300 |
_a142-52 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntiparkinson Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aBasal Ganglia Diseases _xchemically induced |
| 650 | 0 | 4 |
_aBiperiden _xtherapeutic use |
| 650 | 0 | 4 | _aChronic Disease |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 |
_aCyclohexylamines _xtherapeutic use |
| 650 | 0 | 4 | _aEvaluation Studies as Topic |
| 650 | 0 | 4 | _aHandwriting |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMorphinans _xtherapeutic use |
| 650 | 0 | 4 |
_aMovement Disorders _xchemically induced |
| 650 | 0 | 4 |
_aParkinson Disease _xdrug therapy |
| 650 | 0 | 4 | _aPsychiatric Status Rating Scales |
| 650 | 0 | 4 |
_aSchizophrenia _xcomplications |
| 650 | 0 | 4 |
_aSulfonic Acids _xtherapeutic use |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 |
_aTranquilizing Agents _xadverse effects |
| 700 | 1 | _aBeckles, D | |
| 700 | 1 | _aIsalski, Z | |
| 700 | 1 | _aLee, J H | |
| 773 | 0 |
_tThe Journal of clinical pharmacology and new drugs _gvol. 12 _gno. 4 _gp. 142-52 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/j.1552-4604.1972.tb00043.x _zAvailable from publisher's website |
| 999 |
_c4557588 _d4557588 |
||